Last reviewed · How we verify
Miricorilant 100 mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Miricorilant 100 mg (Miricorilant 100 mg) — Corcept Therapeutics.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Miricorilant 100 mg TARGET | Miricorilant 100 mg | Corcept Therapeutics | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Miricorilant 100 mg CI watch — RSS
- Miricorilant 100 mg CI watch — Atom
- Miricorilant 100 mg CI watch — JSON
- Miricorilant 100 mg alone — RSS
Cite this brief
Drug Landscape (2026). Miricorilant 100 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/miricorilant-100-mg. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing